Clinical efficacy of ertapenem for recurrent cystitis caused by multidrug-resistant extended-spectrum β-lactamase-producing escherichia coli in female outpatients

Korean Journal of Urology

Volumn 55, Issue 4, 2014, Pages 270-275

  Song, Sungmin ^a   Kim, Chulsung ^a   Lim, Donghoon ^a  

^a Chosun University   (South Korea)

Author keywords

Bacterial multiple drug resistance; Beta lactams; Cystitis; Ertapenem; Escherichia coli

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; CIPROFLOXACIN; COTRIMOXAZOLE; ERTAPENEM; FOSFOMYCIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; CLINICAL ARTICLE; CYSTITIS; DRUG EFFICACY; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; FEMALE; FOLLOW UP; HUMAN; LOWER URINARY TRACT SYMPTOM; MIDDLE AGED; MULTIDRUG RESISTANCE; NAUSEA; OUTPATIENT CARE; PYURIA; RISK FACTOR; URINE CULTURE; YOUNG ADULT;

EID: 84940277113     PISSN: 20056737     EISSN: 20056745     Source Type: Journal    
DOI: 10.4111/kju.2014.55.4.270     Document Type: Article

References (26)

1. Ronald AR, Nicolle LE, Stamm E, Krieger J, Warren J, Schaeffer A, et al. Urinary tract infection in adults: research priorities and strategies. Int J Antimicrob Agents 2001;17:343-8
2. Valiquette L. Urinary tract infections in women. Can J Urol 2001;8 Suppl 1:6-12
3. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis 1999;29:745-58
4. Hawser SP, Bouchillon SK, Hoban DJ, Badal RE. In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli from patients with intra-abdominal infections worldwide from 2005-2007: results from the SMART study. Int J Antimicrob Agents 2009;34:585-8
5. Chung A, Arianayagam M, Rashid P. Bacterial cystitis in women. Aust Fam Physician 2010;39:295-8
6. Mohsin R, Siddiqui KM. Recurrent urinary tract infections in females. J Pak Med Assoc 2010;60:55-9
7. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase- producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008;8:159-66
8. Shah PM. Parenteral carbapenems. Clin Microbiol Infect 2008;14 Suppl 1:175-80
9. Rodriguez-Bano J, Alcala JC, Cisneros JM, Grill F, Oliver A, Horcajada JP, et al. Community infections caused by extended- spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med 2008;168:1897-902
10. Pitout JD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J Antimicrob Chemother 2005;56:52-9
11. Rodriguez-Bano J, Paterson DL. A change in the epidemiology of infections due to extended-spectrum beta-lactamase-producing organisms. Clin Infect Dis 2006;42:935-7
12. Lee SJ, Lee DS, Choe HS, Shim BS, Kim CS, Kim ME, et al. Antimicrobial resistance in community-acquired urinary tract infections: results from the Korean Antimicrobial Resistance Monitoring System. J Infect Chemother 2011;17:440-6
13. Kim ME, Ha US, Cho YH. Prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in female outpatients in South Korea: a multicentre study in 2006. Int J Antimicrob Agents 2008;31 Suppl 1:S15-8
14. The Korean Society of Infectious Diseases, The Korean Society for Chemotherapy, Korean Association of Urogenital Tract Infection and Inflammation, The Korean Society of Clinical Microbiology. Clinical guideline for the diagnosis and treatment of urinary tract infections: asymptomatic bacteriuria, uncomplicated & complicated urinary tract infections, bacterial prostatitis. Infect Chemother 2011;43:1-25
15. Yang K, Guglielmo BJ. Diagnosis and treatment of extended- spectrum and AmpC beta-lactamase-producing organisms. Ann Pharmacother 2007;41:1427-35
16. Yu Y, Zhou W, Chen Y, Ding Y, Ma Y. Epidemiological and antibiotic resistant study on extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Zhejiang Province. Chin Med J (Engl) 2002;115:1479-82
17. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010; 10:43-50
18. Pullukcu H, Tasbakan M, Sipahi OR, Yamazhan T, Aydemir S, Ulusoy S. Fosfomycin in the treatment of extended spectrum beta- lactamase-producing Escherichia coli-related lower urinary tract infections. Int J Antimicrob Agents 2007;29:62-5
19. Tasbakan MI, Pullukcu H, Sipahi OR, Yamazhan T, Ulusoy S. Nitrofurantoin in the treatment of extended-spectrum β-lactamase- producing Escherichia coli-related lower urinary tract infection. Int J Antimicrob Agents 2012;40:554-6
20. Ramphal R, Ambrose PG. Extended-spectrum beta-lactamases and clinical outcomes: current data. Clin Infect Dis 2006;42 Suppl 4:S164-72
21. Bazaz R, Chapman AL, Winstanley TG. Ertapenem administered as outpatient parenteral antibiotic therapy for urinary tract infections caused by extended-spectrum-beta-lactamase-producing Gram-negative organisms. J Antimicrob Chemother 2010;65: 1510-3
22. Jacoby G, Han P, Tran J. Comparative in vitro activities of carbapenem L-749,345 and other antimicrobials against multiresistant gram-negative clinical pathogens. Antimicrob Agents Chemother 1997;41:1830-1
23. Berg ML, Crank CW, Philbrick AH, Hayden MK. Efficacy of ertapenem for consolidation therapy of extended-spectrum beta-lactamase- producing gram-negative infections: a case series report. Ann Pharmacother 2008;42:207-12
24. Lye DC, Wijaya L, Chan J, Teng CP, Leo YS. Ertapenem for treatment of extended-spectrum beta-lactamase-producing and multidrug- resistant gram-negative bacteraemia. Ann Acad Med Singapore 2008;37:831-4
25. Lee NY, Huang WH, Tsui KC, Hsueh PR, Ko WC. Carbapenem therapy for bacteremia due to extended-spectrum β-lactamase- producing Escherichia coli or Klebsiella pneumoniae. Diagn Microbiol Infect Dis 2011;70:150-3
26. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011;52:e103-20